---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000003"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:45:55.592825+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iBio develops Activin E antibody for obesity; preclinical data shows sub-nanomolar binding

## Summary
- Antibody targeting Activin E for cardiometabolic disorders and obesity, developed with AstralBio Inc.
- Preclinical data: sub-nanomolar binding kinetics and complete blockade of Activin E signaling in human adipocytes.
- Utilized iBio's AI platform to engineer antibodies targeting five epitopes on Activin E protein.
- Corporate presentation updated to reflect the new antibody program; used in investor meetings.

## SEC filing metadata
- accession: 0001420720-25-000003
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000003/0001420720-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000003/ibio-20250110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000003
- JSON: https://secwatch.observer/filing/0001420720-25-000003.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.